Biodelivery Sciences International Inc (BDSI) Q4 2019 Earnings Call Transcript
BDSI earnings call for the period ending December 31, 2019.
BioDelivery Sciences International
BDSI
BDSI
$3.73
-$0.06
-1.6%
Price as of April 1, 2020, 4:30 p.m. EDT
View Interactive BDSI Charts
A biopharmaceutical company that is utilizing its licensed, owned and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties.
Interactive Chart
News & Analysis: BioDelivery Sciences International
Biodelivery Sciences International Inc (BDSI) Q3 2019 Earnings Call Transcript
BDSI earnings call for the period ending September 30, 2019.
BioDelivery Sciences International, Inc. (BDSI) Q2 2019 Earnings Call Transcript
BDSI earnings call for the period ending June 30, 2019.
BioDelivery Sciences International, Inc. (BDSI) Q1 2019 Earnings Call Transcript
BDSI earnings call for the period ending March 31, 2019.
Biodelivery Sciences International Inc (BDSI) Q4 2018 Earnings Conference Call Transcript
BDSI earnings call for the period ending December 31, 2018.
Has Biodelivery Sciences Finally Turned the Corner?
Will Biodelivery Sciences have any more success commercializing Belbuca?
BioDelivery Sciences International's Stock Jumps on FDA Approval
BioDelivery Sciences' shares push higher on the news that the FDA approved the chronic pain medicine Belbuca.
Why Shares in BioDelivery Sciences International, Inc. Are Tumbling
BioDelivery Sciences International, Inc. shares are dropping after the company reported that it's borrowed $20.7 million.
Why Shares in BioDelivery Sciences International, Inc. Burst Today
A key trial failure is sending BioDelivery Sciences International, Inc.'s shares tumbling.
This Week in Biotech: Anacor's FDA A-OK and AbbVie's Insatiable Urge to Buy Something
Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.
